Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

NCT02026362 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: MASCT:Multiple Antigens Specific Cellular Therapy
OTHER: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Sponsor

HRYZ Biotech Co.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]